Zai Lab Limited

What they do

Zai Lab discovers, develops and commercializes medicines in oncology, immunology, neuroscience and infectious disease, operating mainly in Greater China with a growing presence in the United States. Its commercial portfolio of eight approved programs is largely in-licensed from partners, while its proprietary pipeline includes zocilurtatug pelitecan (zoci), a DLL3-targeting ADC, and ZL-1503, an IL-13/IL-31R bispecific antibody. Commercial activities span medical affairs, marketing, market access and distributor management across major medical centers in Greater China.

Revenue drivers

• ZEJULA (niraparib) — Approved in mainland China, Hong Kong and Macau for first-line and platinum-sensitive relapsed ovarian cancer maintenance; second-quarter 2026 revenue was pressured by a shift in hospital utilization after volume-based procurement for generic olaparib, but the company described ZEJULA as stabilizing.
• VYVGART / VYVGART Hytrulo — Approved in mainland China for gMG and CIDP; the company reported double-digit volume growth for VYVGART in the second quarter of 2026, partly offset by a pricing adjustment tied to NRDL renewal.
• NUZYRA and XACDURO — NUZYRA is approved for CABP and ABSSSI in mainland China and Macau, and XACDURO for HABP and VABP caused by ABC in mainland China; both grew in the second quarter of 2026 on expanded market coverage, with XACDURO partly constrained by supply limitations.
• OPTUNE, QINLOCK, AUGTYRO, KarXT — OPTUNE (GBM), QINLOCK (4L GIST) and AUGTYRO (ROS1+ NSCLC and NTRK+ solid tumors) are approved in Greater China; KarXT was launched in mainland China for adult schizophrenia in June 2026 and the company plans to seek NRDL inclusion in 2027.

Recent performance

Second-quarter 2026 total revenue was $106.3 million versus $110.0 million in the prior-year period, with net product revenue of $105.8 million versus $109.1 million. Net product revenue rose 11% sequentially; the year-over-year decline was driven mainly by ZEJULA, due to hospital utilization shifts after volume-based procurement for generic olaparib, and by VYVGART, due to an NRDL-renewal pricing adjustment. R&D expenses rose to $61.8 million from $50.6 million, largely on higher licensing fees, while SG&A was roughly flat at $72.9 million versus $71.0 million. Full-year 2025 revenue was $457.2 million and net loss was $175.5 million, versus $397.6 million of revenue and a $257.1 million net loss in 2024.

Strategy

Zai Lab's stated strategy has three pillars: accelerating medicines to patients through continued R&D investment, expanding and strengthening its pipeline via internal discovery and collaborations, and continuing commercial execution toward profitability. The company is shifting emphasis toward globally differentiated internally developed assets, citing zoci's progression from IND to global Phase 3 in under two years and ZL-1503 as evidence that innovation will drive its next phase of growth. It continues to broaden access for marketed products through NRDL inclusion and supplemental insurance coverage while pursuing U.S. development of its proprietary oncology programs.

Risks

• China commercialization and pricing pressure — Revenue in the second quarter of 2026 fell year over year on a hospital utilization shift after volume-based procurement for generic olaparib and an NRDL-renewal pricing adjustment for VYVGART, showing exposure to Chinese reimbursement and procurement dynamics.
• History of losses and cash use — The company has incurred net losses and negative operating cash flow since inception, including a $175.5 million net loss and $150.8 million of operating cash outflow in 2025, and says it cannot predict when products will become profitable.
• U.S.-China relations and Chinese regulation — The 10-K flags changes in U.S.-China relations and compliance with Chinese laws such as the Counter-Espionage Law, Data Security Law and Personal Information Protection Law as material risks that could entail significant expense.
• Dependence on third parties — The company relies on licensors, CMOs, CROs and distributors, and cites their failure to perform, plus potential GMP or inspection issues at its Chinese manufacturing facilities, as risks to supply and development.

Outlook

Management said the commercial business is positioned for a return to meaningful growth in 2027, with the company planning to further stabilize product sales in the second half of 2026. It expects three registrational studies to be underway by year end and a potential first U.S. regulatory submission in 2027, supporting the global Phase 3 DLLEVATE study of zoci in second-line plus SCLC with enrollment expected to complete in the first half of 2027. Initial first-in-human data for ZL-1503 are expected in the second half of 2026, alongside global Phase 1 data for zoci plus a PD-L1 inhibitor in first-line SCLC at ESMO 2026. KarXT NRDL inclusion will be sought in 2027.